Company news
Oncolytics Biotech Inc. news in 2016
Oncolytics Biotech Inc.'s news releases, calls and decks from 2016, newest first.
Oncolytics Biotech® Inc. Announces Change to Board of Directors
December 6, 2016
Oncolytics Biotech® Inc. Collaborators Present Initial Results from REO 019 Study in Multiple Myeloma Combining REOLYSIN®, Bortezomib and Dexamethasone at the ASH Annual Meeting
December 6, 2016
Oncolytics Biotech® Inc. Announces Appointment of New Chief Medical Officer
November 10, 2016
Oncolytics Biotech® Inc. Announces 2016 Third Quarter Results
November 3, 2016
Media Advisory - Oncolytics Biotech® Inc. Announces Management Team Changes
November 2, 2016
Media Advisory - Oncolytics Biotech® Inc. Announces Participation in the 2016 BIO Investor Forum
October 18, 2016
Media Advisory - Oncolytics Biotech® Inc. Announces Participation in the 4th Annual Immuno-Oncology Summit
August 30, 2016
MEDIA ADVISORY - Oncolytics Biotech® Inc. Announces Participation in the Canaccord Genuity 36th Annual Growth Conference
August 10, 2016
Oncolytics Biotech® Inc. Reports Additional Data from Randomized Phase II Study of REOLYSIN® in Non-Small Cell Lung Cancer
August 10, 2016
Oncolytics Biotech® Inc. Announces 2016 Second Quarter Results
August 4, 2016
Oncolytics Biotech® Inc. Announces Phase 2 Study in Female Patients with Colorectal Cancer Metastatic to the Liver
June 29, 2016
Oncolytics Biotech® Inc. Reports Preliminary Data from Randomized Phase II Study of REOLYSIN® in Colorectal Cancer
May 19, 2016
Oncolytics Biotech® Inc. Reports Preliminary Data from Randomized Phase II Study of REOLYSIN® in Non-Small Cell Lung Cancer
May 19, 2016
Oncolytics Biotech® Inc. Announces 2016 First Quarter Results
May 6, 2016
Oncolytics Biotech® Inc. Announces Presentation of REOLYSIN® Preclinical Research at the 2016 ASGCT Annual Meeting
May 5, 2016
Oncolytics Biotech® Inc. Announces Details of 2016 Annual Meeting of Shareholders
May 3, 2016
Oncolytics Biotech® Inc. to Participate in the Bloom Burton & Co. Healthcare Investor Conference
April 29, 2016
Oncolytics Biotech® Inc. Announces Formation of Science and Technology Committee
April 29, 2016
Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Research at the 2016 AACR Annual Meeting
April 18, 2016
Oncolytics Biotech® Inc. Reports Updated Data from Randomized Phase 2 Study of REOLYSIN® in Pancreatic Cancer
April 14, 2016
Oncolytics Biotech® Inc. Announces Filing of Management Information Circular and Details of 2016 Annual General Meeting
March 24, 2016
Decks in 2016
- Investor Presentation (September 2016)
Investor deck · 31 slides · September 2016